Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080245 · ClinicalTrials.gov registry record · Early Phase 1
Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)
A Early Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04080245 is a Early Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 10 participants.
The verdict
NCT04080245, a Early Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serves as an early biomarker of long-lived antibody responses after vaccination. In this study the investigators will be providing the LAIV to up to 10 healthy subjects and assaying their immune response and then providing the intramuscular influenza vaccination and testing to see if the immune protection after the LAIV also protects after the intramuscular influenza vaccination. Update: We have amended this protocol to study the antigen-specific B cell populations that circulate after LAIV or IIV prime and LAIV or IIV boost.
Interventions
- BIOLOGICAL Treatment Group Live Attenuated Flu Vaccine (LAIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2025-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080245
The ClinicalTrials.gov registry entry for NCT04080245 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment Group Live Attenuated Flu Vaccine (LAIV) is the first listed.
NCT04080245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04080245 about?
NCT04080245 is a clinical study titled "Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)". As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serv...
What is the current status of trial NCT04080245?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-11-15. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT04080245?
The interventions under investigation include: Treatment Group Live Attenuated Flu Vaccine (LAIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04080245?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.